$BMRA as per there filing along with my own opinion, the demand for high quality antibody tests should increase once the vaccine begin to rollout. I should have considered how this 2nd wave interrupts late stage serology initiatives as there is more concern on WHO has it compared to who has developed/is in possession of antibodies for it. I was looking for a quick swing based on good earnings and emergancy use auth. I was not expecting to be humbled this way. If tactical, the poor ER will be cushioned by a nice EUA this week. I really hope this is the case.